Cytological screening of cervical adenocarcinoma;Le dépistage cytologique de l'adénocarcinome du col

Annales de Pathologie

Volumn 32, Issue 6, 2012, Pages 394-400

  Bergeron, Christine ^a   Di Bonito, Luigi ^b  

^a LABORATOIRE CERBA   (France)

^b UNIVERSITY OF TRIESTE   (Italy)

Author keywords

Adenocarcinoma; Bethesda terminology 2001; Cytology; Screening of cervical cancer

Indexed keywords

CANCER MORTALITY; CANCER SCREENING; CERVICAL ADENOCARCINOMA; COLPOSCOPY; FEMALE; HUMAN; PAPILLOMAVIRUS INFECTION; PRECANCER; SHORT SURVEY; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CYTOLOGY;

EID: 84871029700     PISSN: 02426498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.annpat.2012.09.199     Document Type: Short Survey

References (26)

1. Bray F., Carstensen B., Moller H., Zappa M., Zakelj M.P., Lawrence G., et al. Incidence trends of adenocarcinoma of the cervix in 13 European countries. Cancer Epidemiol Biomarkers Prev 2005, 14:2191-2199.
2. Ries L., Harkins D., Krapcho M., Mariotto A., Miller B.A., Feurer E.J., et al. SEER cancer statistics review, 1975-2003 2003, National Cancer Institute, Bethesda, MD, [available at http://seer.cancer.gov/csr/1975_2003/-24k-2010-06-28].
3. Sasieni P., Adams J. Changing rates of adenocarcinoma and adenosquamous carcinoma of the cervix in England. Lancet 2001, 357:1490-1493.
4. Zappa M., Visioli C.B., Ciatto S., Iossa A., Paci E., Sasieni P. Lower protection of cytological screening for adenocarcinoma and shorter protection for younger women: the results of a case-control in Florence. Br J Cancer 2004, 90:1784-1786.
5. Sherman M.E., Wang S.S., Carreon J., Devesa S.S. Mortality trends for cervical squamous and adenocarcinoma in the United States: relation to incidence and survival. Cancer 2005, 103:1258-1264.
6. Wells M., Ostor A.G., Crum C.P., Franceschi S., Tommasino M., Nesland J.M., et al. Epithelial tumours, tumours of the uterine cervix. Tumours of the Breast and female genital organs 2003, WHO IARC, Lyon, [pp. 262-79]. P. Tavassoli Fand Devilee (Ed.).
7. Plaxe S.C., Saltzstein S.L. Estimation of the duration of the preclinical phase of cervical adenocarcinoma suggests that there is ample opportunity for screening. Gynecol Oncol 1999, 75:55-61.
8. Lee K.R., Flynn C.E. Early invasive adenocarcinoma of the cervix. Cancer 2000, 89:1048-1055.
9. Castellsague X., Diaz M., de Sanjose S., Munoz N., Herrero R., Franceschi S., et al. Worlwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst 2006, 98:303-315.
10. Ruba S., Schoolland M., Allpress S., Sterrett G. Adenocarcinoma in situ of the uterine cervix: screening and diagnostic errors in Papanicolaou smears. Cancer 2004, 102:280-287.
11. Ansari-Lari M.A., Staebler A., Zaino R.J., Shah K.V., Ronnett B.M. Distinction of endocervical and endometrial adenocarcinoma: immunohistochemical p16 expression correlated with human papillomavirus (HPV) DNA detection. Am J Surg Pathol 2004, 28:160-167.
12. Kalir T., Simsir A., Demopoulos H.B., Demopoulos R.I. Obstacles to the early detection of endocervical adenocarcinoma. Int J Gynecol Pathol 2005, 24:414-421.
13. Solomon D., Davey D., Kurman R., Moriarty A., Connor O.D., Prey, et al. The 2001 Bethesda System. Terminology for reporting results of cervical cytology. JAMA 2002, 287:2114-2119.
14. Schneider V. Cytopathology of Adenocarcinoma in situ of the endocervix and its differential diagnosis. Monogr Clin Cytol 2011, 20:26-33. [Epub 2010 Dec 10].
15. Bergeron C., Cartier I., Guldner L., Lassalle M., Savignon A., Asselain B. Lésions précancéreuses et cancers du col de l'utérus diagnostiqués par le frottis cervical. île-de-France, enquête Crisap, 2002. BEH 2005, 2:4-5.
16. Jones B.A., Novis D.A. Follow-up of abnormal gynaecologic cytology: a College of American pathologists Q-Probes study of 16,132 cases from 306 laboratories. Arch Pathol Lab Med 2000, 124:665-671.
17. Laverty C.R., Farnsworth A., Thurloe J., Bowditch R. The reliability of a cytological prediction of cervical adenocarcinoma in situ. Aust N Z J Obstet Gynecol 1988, 28:307-312.
18. Lee K.R., Manna E.A., St John T. Atypical endocervical glandular cells: accuracy of cytological diagnosis. Diagn Cytopathol 1995, 13:202-208.
19. Westin M.C., Derchain S.F., Rabelo-Santos S.H., Angelo-Andrade L.A., Sarian L.O., Oliveira E., et al. Atypical glandular cells and adenocarcinoma in situ according to Bethesda 2001 Classification cytohistological correlation and clinical implications. Eur J Obstet Gynecol Reprod Biol 2008, 13:79-85.
20. Adhya A.K., Mahesha V., Srinivasan R., Nijhawan R., Rajwanshi A., Suri V., et al. Atypical glandular cells in cervical smears-histological correlation and a suggested plan of management based on age of the patient in a low resource setting. Cytopathology 2009, 20:375-379.
21. Chieng D.C., Elgert P., Cohen J.M., Cangiarella J.F. Clinical significance of atypical glandular cells of undetermined significance in postmenopausal women. Cancer 2001, 93:1-7.
22. Wright T.C., Massad L.S., Dunton C.J., Spitzer M., Wilkinson E.J., Solomon D. 2006 Consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol 2007, 197:346-355.
23. H.A.S. Clinical practice guidelines. Management of a patient with an abnormal cervical smear, update 2002, [available at: http://www.has-sante.fr/portail/upload/docs/application/pdf/frottis_anglais.pdf].
24. Liao S.Y., Rodgers W.H., Kauderer J., Bonfiglio T.A., Walker J.L., Darcy K.M., et al. Carbonic anhydrase IX (CA-IX) and human papillomavirus (HPV) as diagnostic biomarkers of cervical dysplasia/neoplasia in women with a cytologic diagnosis of atypical glandular cells (AGC): a Gynecologic Oncology Group (GOG) Study. Int J Cancer 2009, 125:2434-2440.
25. Saqi A., Gupta P.K., Erroll M., Babiac A., Blackmun D., Mansukhani M., et al. High-risk human papillomavirus DNA testing: a marker for atypical glandular cells. Diag Cytopathol 2006, 34:235-239.
26. Mitchell H., Hocking J., Saville M. Improvement in protection against adenocarcinoma of the cervix resulting from participation in cervical screening. Cancer 2003, 99:336-341.